TH1701003624A - Bialryl derivative of GPR120 agonist form. - Google Patents
Bialryl derivative of GPR120 agonist form.Info
- Publication number
- TH1701003624A TH1701003624A TH1701003624A TH1701003624A TH1701003624A TH 1701003624 A TH1701003624 A TH 1701003624A TH 1701003624 A TH1701003624 A TH 1701003624A TH 1701003624 A TH1701003624 A TH 1701003624A TH 1701003624 A TH1701003624 A TH 1701003624A
- Authority
- TH
- Thailand
- Prior art keywords
- bialryl
- derivative
- chemical formula
- liver disease
- fatty liver
- Prior art date
Links
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 title claims abstract 3
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 title claims abstract 3
- 239000000556 agonist Substances 0.000 title claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 5
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract 2
- 206010012655 Diabetic complications Diseases 0.000 claims abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract 2
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims abstract 2
- 239000000470 constituent Substances 0.000 claims abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 208000010706 fatty liver disease Diseases 0.000 claims abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract 2
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 2
- 230000002757 inflammatory effect Effects 0.000 claims abstract 2
- 210000004185 liver Anatomy 0.000 claims abstract 2
- 210000002540 macrophage Anatomy 0.000 claims abstract 2
- 208000030159 metabolic disease Diseases 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 210000003205 muscle Anatomy 0.000 claims abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Abstract
แก้ไข 21 ก.ย. 2560 การประดิษฐ์นี้เกี่ยวข้องกับอนุพันธ์ไบอัลริลที่แสดงออกโดยสูตรทางเคมี 1, วิธีการ สำหรับการผลิตอนุพันธ์ไบอัลริล, องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสิ่งที่เหมือนกัน, และ การใช้ของสิ่งที่เหมือนกัน, อนุพันธ์ไบอัลริลที่แสดงออกโดยสูตรทางเคมี 1, ในรูป GPR120 อะโกนิสต์, ที่สนับสนุนการสร้าง GLP-1 ในทางเดินอาหาร, ที่ลดการดื้อต่ออินซูลินในตับ, กล้ามเนื้อและอื่น ๆ จาก แอคติวิตี้ต่อต้านการอักเสบในแมคโครฟาจ, เซลล์ตับอ่อนและอื่น ๆ, และการยอมให้การใช้ที่มี ประสิทธิภาพในการป้องกันหรือการรักษาของการอักเสบหรือโรคทางเมทาบอลิค เช่น โรคเบาหวาน, โรคแทรกซ้อนจากโรคเบาหวาน, ภาวะอ้วนมากเกิน, โรคไขมันพอกตับที่ไม่ได้เกิดจากแอลกอฮอล์, โรคไขมันพอกตับ, และภาวะกระดูกพรุน สิทธิบัตรยา Revised Sept. 21, 2017, this invention relates to a bi-aryl derivative expressed by chemical formula 1, a method for the production of a biarril derivative, a pharmaceutical constituent containing inclusions, And using the same, a Bialryl derivative expressed by chemical formula 1, in the form of GPR120 agonists, that supports GLP-1 formation in the gastrointestinal tract, which reduces insulin resistance. In the liver, muscles and others from the anti-inflammatory activity in macrophages, pancreatic cells and others, and its use with Effective in the prevention or treatment of inflammatory or metabolic diseases such as diabetes mellitus, diabetic complications, obesity, non-alcoholic fatty liver disease, fatty liver disease, and Osteoporosis, drug patent
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH1701003624A true TH1701003624A (en) | 2019-06-21 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016105118A3 (en) | Biaryl derivative as gpr120 agonist | |
| MX357780B (en) | Polycyclic derivatives, preparation method and medical uses thereof. | |
| HK1213483A1 (en) | Dual glp1/gip or trigonal glp1/gip/glucagon agonists | |
| MX2015016543A (en) | Biaryl derivatives as gpr120 agonists. | |
| WO2013106226A3 (en) | Methods of treating or preventing insulin resistance and associated diseases and conditions | |
| NZ729455A (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
| TH1701003624A (en) | Bialryl derivative of GPR120 agonist form. | |
| WO2015042495A3 (en) | Metformin salts to treat type2 diabetes | |
| TH162726A (en) | Biaryl derivative, which is GPR120 agonist. | |
| TH165228A (en) | Amide Derivatives for GPR119 Agonists | |
| JP2014031330A5 (en) | ||
| WO2016041906A3 (en) | Manipulation of hairy and enhancer of split 3 (hes3) and its regulators/mediators in diabetes, obesity, and metabolic syndrome | |
| TH166727A (en) | Azadamantane Derivatives and Their Use | |
| WO2014122575A3 (en) | Fatty acid conjugates for the treatment of inflammation and metabolic diseases | |
| TH158546A (en) | Excendin-4 derivatives That is the operator GLP1 / Double Glucagon | |
| TH151388A (en) | Pharmaceutical components including pyrion derivatives | |
| TH1401007609A (en) | A new compound with the ability to inhibit the enzyme 11 beta-HSD1, or the chemically acceptable salt of the above. A method for producing the same thing. And pharmaceutical compounds with the same active ingredients. | |
| Wallace | S5-1 H2S-based therapeutics for inflammatory diseases | |
| TH130488A (en) | 5- (3,4-dichloro-phenyl) -N- (2- hydroxy-cyclohexyl) -6- (2,2,2-trifluoro-ethok C) - nicotinamide (5- (3-4-dichloro-phenyl) -N- (2-hydroxy-cyclohexyl) -6- (2,2,2-trifluoro-ethoxy) -nicotinamide) and salt. Of the said substance | |
| TH153171A (en) | The phenylasol derivative which is replaced | |
| TH1501002696A (en) | ||
| TH112738A (en) | Heterocyclic derivatives | |
| TH168833A (en) | Azolbenzene derivatives | |
| TH155599A (en) | Partially saturated tricyclic compounds and methods for their production and use. | |
| TH168637A (en) | New heterocyclic compounds |